<DOC>
	<DOCNO>NCT00450866</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , epothilone B , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well epothilone B work treat patient CNS metastasis breast cancer .</brief_summary>
	<brief_title>Epothilone B Treating Patients With CNS Metastases From Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 3-month CNS-progression free survival patient CNS metastases secondary breast cancer treat epothilone B . Secondary - Determine toxicity drug patient . - Determine CNS response rate duration CNS response patient treated drug . - Determine systemic disease response rate duration systemic response patient treated drug . - Determine overall survival patient treated drug . OUTLINE : This multicenter , open-label study . Patients receive epothilone B IV 20 minute day 1 . Courses repeat every 21 day absence disease progression , satisfactory response , unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 55 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm carcinoma breast CNS metastasis ( i.e. , brain parenchymal lesion and/or leptomeningeal disease ) , meet 1 follow criterion : Recurrent progressive CNS metastasis whole brain radiotherapy If evaluable site CNS progression previously treat stereotactic radiosurgery , radiation necrosis must exclude radiographic ( e.g. , positron emission tomography scan magnetic resonance spectroscopy ) histologic assessment Newly diagnose , untreated , asymptomatic brain leptomeningeal metastasis Patient must neurologically stable , demonstrate stable dose steroid anticonvulsant ≥ 1 week prior obtain baseline gadoliniumenhanced MRI brain and/or ≥ 1 week prior begin study treatment No CNS complication require urgent neurosurgical intervention ( e.g. , resection shunt placement ) Hormone receptor status specify PATIENT CHARACTERISTICS : Male female Menopausal status specify Karnofsky performance status 60100 % Life expectancy ≥ 3 month Absolute neutrophil count &gt; 1,500/mm^3 Hemoglobin &gt; 9.0 g/dL Platelet count &gt; 100,000/mm^3 ( red blood cell transfusion repeat evaluation allow ) Bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST ALT &lt; 2.5 time ULN Alkaline phosphatase &lt; 2.5 time ULN Creatinine &lt; 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study therapy No known hypersensitivity epothilones No peripheral neuropathy &gt; grade 1 No unresolved diarrhea within past 7 day Grade 0 diarrhea require study entry No concurrent serious medical illness ( e.g. , HIV positivity active hepatitis B C ) No severe cardiac insufficiency ( e.g. , New York Heart Association class IIIIV heart disease ) uncontrolled and/or unstable cardiac coronary artery disease No active suspect acute chronic uncontrolled infection , include abscess fistula No malignancy within past 3 year except curatively treat nonmelanoma skin cancer , prostate cancer , carcinoma situ cervix No history noncompliance medical regimen inability unwillingness return schedule visit No contraindication MRI , include follow : Pacemaker Ferromagnetic implant Claustrophobia Extreme obesity PRIOR CONCURRENT THERAPY : See Disease Characteristics More 2 week since prior noncytotoxic drug ( e.g. , small moleculetargeted drug ) recover More 3 week since prior cytotoxic chemotherapy ( 6 week nitrosoureas mitomycin C ) recover More 3 week since prior intracranial surgery recover More 4 week since prior radiotherapy recover More 4 week since prior major surgery More 28 day since prior investigational compound drug No prior epothilones No concurrent know diarrheagenic agent No concurrent anticancer agent , include investigational agent , biological agent , chemotherapy No concurrent experimental therapy Concurrent hormone therapy and/or trastuzumab ( Herceptin® ) allow No concurrent Coumadin® agent contain warfarin Low dose Coumadin® ( ≤ 1 mg ) prophylactic maintenance indwell line port allow No concurrent radiotherapy central metastasis ( e.g. , vertebral mediastinal metastasis ) Concurrent radiotherapy local peripheral metastasis use marker lesion allow No concurrent prophylactic hematopoietic growth factor course 1 No concurrent herbal nontraditional medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>tumor metastatic brain</keyword>
	<keyword>leptomeningeal metastasis</keyword>
	<keyword>male breast cancer</keyword>
</DOC>